Praxis Precision Medicines targets FDA approvals for two therapies by early 2027 and forecasts $10B peak sales for ulixacaltamide.
Praxis Precision Medicines (PRAX) expects FDA decisions on two new drug applications within six months, aiming for approvals by early 2027. The company projects peak sales of $10B for its lead candidate, ulixacaltamide, and is expanding its field force to approximately 300 personnel.
Management confirmed both NDAs are in late-stage review, with no prior approvals for these therapies. The $10B sales projection reflects long-term commercial potential, though no consensus estimates were provided for comparison.
Shares of PRAX showed limited immediate reaction during the earnings call, as investors await further regulatory updates.